Celcuity Reports $43.8 Million Net Loss in Q3 2025, Cash Reserves Increase to $74.3 Million

Celcuity Inc. reported significant financial developments in its latest 10-Q filing for the third quarter of 2025, revealing a net loss of approximately $43.8 million for the three months ended September 30, 2025, compared to a net loss of $29.8 million for the same period in 2024. For the nine months ended September 30, 2025, the company recorded a net loss of $126.1 million, up from $75.1 million in the prior year. The increase in losses is attributed to a 43% rise in total operating expenses, which reached $42.8 million for the quarter, driven primarily by a 27% increase in research and development costs and a 221% increase in general and administrative expenses.

In terms of liquidity, Celcuity's cash and cash equivalents surged to approximately $74.3 million as of September 30, 2025, up from $22.5 million at the end of 2024. This increase was bolstered by the completion of a public equity offering in July 2025, which generated net proceeds of approximately $91.6 million, and a convertible notes offering that raised about $194.9 million. The company also reported total current assets of $475.5 million, significantly higher than the $244.6 million reported at the end of 2024, reflecting a strategic focus on enhancing its financial position to support ongoing clinical trials.

Operationally, Celcuity is advancing its lead therapeutic candidate, gedatolisib, through multiple clinical trials. The Phase 3 VIKTORIA-1 trial has completed enrollment, and topline data is expected in early 2026. The company is also actively enrolling patients in the VIKTORIA-2 trial and has initiated a Phase 1b/2 trial, CELC-G-201, for patients with metastatic castration-resistant prostate cancer. As of September 30, 2025, a total of 492 patients have received gedatolisib across various trials, indicating a growing engagement in clinical research.

The filing also highlighted a strategic amendment to the company's loan agreement, which increased the potential borrowing capacity to support ongoing clinical development. The company anticipates that its current cash reserves, along with the proceeds from recent financing activities, will be sufficient to fund operations through 2027. However, Celcuity acknowledges the need for additional capital to support future growth and commercialization efforts, particularly as it approaches potential FDA approval for gedatolisib. The company remains focused on its clinical development strategy while navigating the complexities of the biotechnology market.